Shaanxi Kanghui Pharm Co Ltd (603139) - Total Assets
Based on the latest financial reports, Shaanxi Kanghui Pharm Co Ltd (603139) holds total assets worth CN¥1.71 Billion CNY (≈ $249.51 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Shaanxi Kanghui Pharm Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Shaanxi Kanghui Pharm Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Shaanxi Kanghui Pharm Co Ltd (603139) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Shaanxi Kanghui Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shaanxi Kanghui Pharm Co Ltd's total assets of CN¥1.71 Billion consist of 32.5% current assets and 67.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.9% |
| Accounts Receivable | CN¥226.74 Million | 12.5% |
| Inventory | CN¥163.14 Million | 9.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥86.29 Million | 4.8% |
| Goodwill | CN¥7.49 Million | 0.4% |
Asset Composition Trend (2012–2025)
This chart illustrates how Shaanxi Kanghui Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shaanxi Kanghui Pharm Co Ltd (603139) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shaanxi Kanghui Pharm Co Ltd's current assets represent 32.5% of total assets in 2025, a decrease from 73.6% in 2012.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, down from 14.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 12.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 12.5% of total assets.
Shaanxi Kanghui Pharm Co Ltd Competitors by Total Assets
Key competitors of Shaanxi Kanghui Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Shaanxi Kanghui Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 0.95 | 5.59 |
| Quick Ratio | 0.41 | 0.67 | 4.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-329.06 Million | CN¥-32.98 Million | CN¥666.05 Million |
Shaanxi Kanghui Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shaanxi Kanghui Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.88 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | CN¥1.81 Billion |
| Market Capitalization | $660.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shaanxi Kanghui Pharm Co Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shaanxi Kanghui Pharm Co Ltd's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shaanxi Kanghui Pharm Co Ltd (2012–2025)
The table below shows the annual total assets of Shaanxi Kanghui Pharm Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.81 Billion ≈ $265.51 Million |
-3.89% |
| 2024-12-31 | CN¥1.89 Billion ≈ $276.25 Million |
-7.99% |
| 2023-12-31 | CN¥2.05 Billion ≈ $300.23 Million |
+12.63% |
| 2022-12-31 | CN¥1.82 Billion ≈ $266.57 Million |
-2.07% |
| 2021-12-31 | CN¥1.86 Billion ≈ $272.21 Million |
+41.87% |
| 2020-12-31 | CN¥1.31 Billion ≈ $191.87 Million |
+15.97% |
| 2019-12-31 | CN¥1.13 Billion ≈ $165.45 Million |
+1.85% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.46 Million |
+7.60% |
| 2017-12-31 | CN¥1.03 Billion ≈ $150.99 Million |
+57.54% |
| 2016-12-31 | CN¥654.97 Million ≈ $95.84 Million |
+13.24% |
| 2015-12-31 | CN¥578.40 Million ≈ $84.64 Million |
+13.94% |
| 2014-12-31 | CN¥507.65 Million ≈ $74.28 Million |
+12.81% |
| 2013-12-31 | CN¥450.00 Million ≈ $65.85 Million |
+42.52% |
| 2012-12-31 | CN¥315.74 Million ≈ $46.20 Million |
-- |
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers gynecological, orthopedic, dermatology, diabetes, respiratory system, urinary system, cardiovascular, tranquilizer, gastrointestinal, hepatobiliary, and other drugs in the form of tablets, capsules, granules, mixtures, teas, plasters, ointments, lin… Read more